Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @SofinnovaParis
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @SofinnovaParis
-
How do you spot a
#biotech winner? Our managing partner Antoine Papiernik gives insight into his process in this member exclusive Q&A with@Labiotech_eu. https://bit.ly/365yZS1#investingHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Biotalys announces collaboration with Chrysal to evaluate potential of biofungicide in flowers http://bit.ly/2v89UZA
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sofinnova Partners is pleased to announce the promotion of Michael Krel to partner. Learn more: https://bit.ly/2TBYkA2
#industrialbiotech#biotechnologypic.twitter.com/qgYgVNy451
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sofinnova Partners proslijedio/la je Tweet
Health care sector has $1T in investing ‘firepower’: Investor http://ow.ly/qppe30q9M5J
@MorningsMaria@FoxBusinessHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
“2020 could be the year of
#neuroscience,” Antoine Papiernik predicts in his recent interview with@MariaBartiromo, where the pair delved into topics ranging from scientific innovation to a look forward at the potential in#healthcare#investing:https://bit.ly/2RqeQ3JHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sofinnova Partners Announces the Promotion of Michael Krel to Partner of Industrial Biotechnology Team http://bit.ly/2NHOLMz
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
HOOKIPA’s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines Advancing Towards Clinical Entry http://bit.ly/39JlV7D
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
MedDay Reports Last Patient Study Visit in Phase 3 Clinical Trial with MD1003®*, an Important Step Towards Completion of the SPI2 Study in Progressive Multiple Sclerosis http://bit.ly/2PqvArO
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock http://bit.ly/34b3QMJ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
TISSIUM Closes €39M Series B Funding Round http://bit.ly/2XHCVpq
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Avantium nominates Edwin Moses as Chairman of its Supervisory Board http://bit.ly/2JW4Wnt
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sofinnova Partners proslijedio/la je Tweet
Sofinnova said it “will seek to invest as a founding and lead investor in start-ups and corporate spin-offs, and focus on therapeutic, paradigm-shifting technologies and products alongside visionary entrepreneurs.”:https://www.fiercebiotech.com/biotech/european-vc-sofinnova-raises-eu333m-for-early-stage-biotech-medtech-firms …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sofinnova Partners proslijedio/la je Tweet
Sofinnova builds stacks [on stacks, on stacks] for early-stagehttps://endpts.com/sofinnova-builds-stacks-on-stacks-on-stacks-for-early-stage/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sofinnova Partners proslijedio/la je Tweet
French VC Sofinnova Partners will continue to invest in early stage start-ups with its €333 million ninth core fundhttps://buff.ly/2MLw1dH
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sofinnova Partners’ Antoine Papiernik joined other thought leaders to discuss France as a blueprint for European
#VentureCapital at#VCForum2019
@InvestEuropeEUpic.twitter.com/QduvZJnOqE
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sofinnova Partners proslijedio/la je Tweet
France as a blueprint for European VC evolution: our first panel of the day w/
@jeanbourcereau of@Ventech_VC,@APapiernik of@SofinnovaParis,@fleurpellerin of@korelyacapital,@roxannevarza of@joinstationf and@PascalCagni@businessfrance#VCForum2019#VentureCapitalpic.twitter.com/N7wsniBjid
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Pleased to announce the close of our latest early-stage
#healthcare venture capital fund, Sofinnova Capital IX: https://bit.ly/2VPUq5T#investingpic.twitter.com/1fjyJhmVQW
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We have added a new early-stage venture capital fund to our comprehensive platform of life sciences-focused
#investment vehicles. Learn more: https://bit.ly/2VPUq5T pic.twitter.com/Ia4860F6uv
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
SOFINNOVA PARTNERS RAISES €333 MILLION CAPITAL IX EARLY-STAGE HEALTHCARE FUND http://bit.ly/2oQ9MLt
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares http://bit.ly/35CYye3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.